Mylan $800 million acquisition of Famy Care women's health units

Overview:

• Mylan has acquired the women's health care business of Indian firm Famy Care for $800 million.
• The deal consists of an initial $750 million payment with $50 million in contingent payments.
• Famy Care produces contraceptives, intra-uterine devices and hormone-replacement therapies and is the world’s largest producer of generic oral contraceptive pills.
• The acquisition is part of the US generic drug firm's strategy to break into emerging markets in the contraceptives field.
• The deal follows Mylan's 2014 acquisition of Abbott Laboratories.
• Cravath Swaine & Moore (Mark Greene and Minh Van Ngo) acted for Mylan alongside Luthra & Luthra (Mohit Saraf) as Indian counsel.
• Covington & Burling (Jack Bodner and Ralph Voltmer) acted for Famy Care alongside AZB & Partners (Shuva Mandal) and Crawford Bayley & Co (Sanjay Asher) as Indian counsel.
• Debevoise & Plimpton (Geoff Burgess) acted for Famy shareholder AIF Capital alongside Platinum Partners (Ankit Majmudar) as Indian counsel.